Technology Review - Published By MIT
Advertisement
TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.
I'm a paid subscriber please
log me in
I want to purchase this article for
only $1.99
(requires login)
I want to purchase five articles for
only $7.99
(requires login)
I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

October 2003

Mapping a Stem Cell Policy

European countries are imposing a patchwork of tough restrictions that are impeding research.

By Erika Jonietz

Embryonic stem cells, with their unique power to differentiate into every type of cell in the human body, have been hailed as the source of possible cures for everything from heart disease to Parkinson's but reviled by antiabortion activists, who oppose harvesting the cells from surplus frozen embryos. When the U.S. government decided in 2001 to deny funding for research that uses embryonic cells derived after August 9, 2001, observers predicted a brain drain of U.S. researchers to Europe.

Select from the choices above
to read the entire article.


Log In

Forgot your password?     Register »
Advertisement

Videos

Laser-Triggered Chemical Reactions
Advertisement
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2009 Technology Review. All Rights Reserved.